Intra-articular injection Conjuran can be reimbursed

Competition for generic products has begun in earnest, including PharmaReaserch 'Conjuran'

The HIRA applies benefit standards in June

As the age of aging population begins in earnest, the number of osteoarthritis patients is increasing, and the market for related treatments is also heating up.

 

Competition among pharmaceutical companies is fierce as various products of "Intra-articular injection," which has recently been in the spotlight, are newly included in the benefit.

 

According to the pharmaceutical industry on the 23rd, the HIRA has recently been confirmed to have changed the reimbursement standard related to "treatment materials for Intra-articular," which is called joint strength injections, since June.

 

Collagen is added to the existing intra-pulmonary infusion treatment material.

 

Specifically, patients with knee osteoarthritis were added not only sodium polynucleotide but also collagen, including a total of two components of joint strength injections.

 

An official from the HIRA said, "The addition of collagen is the result of the application for the benefit registration while the related products are recognized as new medical technology." The HIRA clarified the method and number of injections with Polynucleotide administered up to five doses per six months and collagen administered up to five doses per six months (within 180 mg of total collagen dose).

 

These categories set patient copayment rate of 80% for Selective Health Benefit targets.

 

PharmaReaserch's Conjuran is a Polynucleotide-based joint strength injection, and CartiZol is a collagen-based joint strength injection.

 

Among them, PharmaReaserch's Conjuran has been subject to Selective Health Benefit since the second half of last year, leading the osteoarthritis treatment market as the administration of patients has increased, led by orthopedic and rehabilitation clinics.

 

Recently, it had an influence on general hospitals by conducting a co-promotion with SK chemicall.

 

Conjuran began competition with Sewoncellontech's CartiZol, a collagen-based injection of joint strength.

 

Due to the increase in arthritis patients due to the aging population, competitors such as CGBIO also predicted challenges in the joint steel injection market.

 

Osteoarthritis treatments market is growing.

 

According to the NHIS, the number of arthritis patients increased by about 10% in five years from 4.4 million in 2014 to 4.86 million in 2018.

 

"As the population ages and the number of patients with knee osteoarthritis increases, joint strength injections are in the spotlight recently," an official from a pharmaceutical company said.

 

"In particular, the treatment market will begin to compete with companies." "The current market for this treatment is worth ₩100 billion a year, and it will grow year by year," he predicted